Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of PF-06882961 in Chinese Adults With Type 2 Diabetes Mellitus

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04889157
Recruitment Status : Completed
First Posted : May 17, 2021
Last Update Posted : March 14, 2022
Information provided by (Responsible Party):

Brief Summary:
This is a Phase 1, randomized, double-blind (sponsor open), placebo controlled study in adult Chinese participants with T2DM who are receiving metformin as background antihyperglycemic medication.

Condition or disease Intervention/treatment Phase
Diabetes Mellitus, Type 2 Drug: PF-06882961 Drug: Placebo Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 20 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Basic Science
Actual Study Start Date : July 7, 2021
Actual Primary Completion Date : February 17, 2022
Actual Study Completion Date : February 17, 2022

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: PF-06882961
Participants will be titrated up to 6 weeks of the 8-week dosing duration to reach desired dose level 120 mg
Drug: PF-06882961
Participants will be administered active doses, taking 3 tablets twice daily (BID) for 8 weeks except Day 1 (QD)

Placebo Comparator: Placebo
Drug: Placebo
3 matching placebo tablets taken twice daily (BID) except Day 1 (QD)

Primary Outcome Measures :
  1. Area under the concentration-time curve [ Time Frame: 0, 1, 2, 4, 6, 8, 10, 12, 14 and 24 hours on Days 1, 21, 35 and 56 ]
  2. Maximum observed plasma concentration [ Time Frame: 0, 1, 2, 4, 6, 8, 10, 12, 14 and 24 hours on Days 1, 21, 35 and 56 ]

Secondary Outcome Measures :
  1. Number of participants with clinically significant change from baseline in vital signs [ Time Frame: Baseline up to 14 days after last dose (Day 70) ]
  2. Number of participants with abnormal Electrocardiogram (ECG) [ Time Frame: Baseline up to 14 days after last dose (Day 70) ]
  3. Number of participants with treatment emergent treatment-related adverse events [ Time Frame: Baseline up to 35 days after last dose (Day 91) ]
  4. Number of participants with laboratory abnormalities [ Time Frame: Baseline up to 14 days after last dose (Day 70) ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   20 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with T2DM who are taking metformin monotherapy as their only antihyperglycemic treatment
  • HbA1c greater than or equal to 7% and less than or equal to 10.5%
  • Total body weight >50 kg (110 lb) with BMI of 22.5 to 45.4 kg/m^2

Exclusion Criteria:

  • Any condition possibly affecting drug absorption
  • Diagnosis of Type 1 diabetes mellitus or secondary forms of diabetes
  • History of myocardial infarction, unstable angina, arterial revascularization, stroke, heart failure, or transient ischemic attack within 6 months of Screening
  • Any malignancy not considered cured
  • Personal or family history of MTC or MEN2, or participants with suspected MTC
  • Acute pancreatitis or history of chronic pancreatitis
  • Acute gallbladder disease
  • Known history of HIV, hepatitis B, hepatitis C or syphilis, or positive testing of them
  • Supine blood pressure greater than or equal to 160 mmHg (systolic) or greater than or equal to 100 mmHg (diastolic)
  • Clinically relevant ECG abnormalities
  • Positive urine drug test
  • Clinical relevant laboratory tests abnormalities

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04889157

Layout table for location information
Peking University Third Hospital
Beijing, China, 100089
Sponsors and Collaborators
Layout table for investigator information
Study Director: Pfizer Call Center Pfizer
Additional Information:
Layout table for additonal information
Responsible Party: Pfizer Identifier: NCT04889157    
Other Study ID Numbers: C3421028
First Posted: May 17, 2021    Key Record Dates
Last Update Posted: March 14, 2022
Last Verified: March 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at:

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases